Published in J Biol Chem on October 29, 2002
Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature (2012) 5.47
The GSK3 hypothesis of Alzheimer's disease. J Neurochem (2007) 3.16
Mechanisms of tau-induced neurodegeneration. Acta Neuropathol (2009) 2.27
GSK3beta phosphorylation modulates CLASP-microtubule association and lamella microtubule attachment. J Cell Biol (2009) 1.95
Resolution of the nuclear localization mechanism of glycogen synthase kinase-3: functional effects in apoptosis. J Biol Chem (2007) 1.46
Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J (2008) 1.43
Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neurochem (2008) 1.38
Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation. Eur J Neurosci (2007) 1.36
Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci (2013) 1.32
Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med (2007) 1.21
Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52. Nat Commun (2014) 1.17
Anesthesia-induced hyperphosphorylation detaches 3-repeat tau from microtubules without affecting their stability in vivo. J Neurosci (2008) 1.15
Phosphorylation controls CLIMP-63-mediated anchoring of the endoplasmic reticulum to microtubules. Mol Biol Cell (2005) 1.13
PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners. FEBS Lett (2006) 1.12
Microtubule-associated protein tau is essential for long-term depression in the hippocampus. Philos Trans R Soc Lond B Biol Sci (2013) 1.10
Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model. Hum Mol Genet (2008) 1.09
The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol (2013) 1.05
Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer's disease. Hum Mol Genet (2010) 1.01
Lysosomal alkalization and dysfunction in human fibroblasts with the Alzheimer's disease-linked presenilin 1 A246E mutation can be reversed with cAMP. Neuroscience (2014) 0.97
GSK-3 in Neurodegenerative Diseases. Int J Alzheimers Dis (2011) 0.97
Tau potentiates nerve growth factor-induced mitogen-activated protein kinase signaling and neurite initiation without a requirement for microtubule binding. J Biol Chem (2010) 0.96
Dysregulation of protein phosphorylation/dephosphorylation in Alzheimer's disease: a therapeutic target. J Biomed Biotechnol (2006) 0.96
Phosphorylation of neuronal survival factor MEF2D by glycogen synthase kinase 3beta in neuronal apoptosis. J Biol Chem (2009) 0.96
Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. Int J Alzheimers Dis (2011) 0.94
A DNA damage-activated checkpoint kinase phosphorylates tau and enhances tau-induced neurodegeneration. Hum Mol Genet (2010) 0.93
Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity. Biochem J (2014) 0.93
Pseudohyperphosphorylation has differential effects on polymerization and function of tau isoforms. Biochemistry (2011) 0.90
An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease. J Biol Chem (2013) 0.90
Inhibition of cyclin-dependent kinase 5 but not of glycogen synthase kinase 3-β prevents neurite retraction and tau hyperphosphorylation caused by secretable products of human T-cell leukemia virus type I-infected lymphocytes. J Neurosci Res (2011) 0.88
Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin. Acta Neuropathol (2009) 0.88
Developing pharmacological therapies for Alzheimer disease. Cell Mol Life Sci (2007) 0.87
A noncatalytic domain of glycogen synthase kinase-3 (GSK-3) is essential for activity. J Biol Chem (2010) 0.87
Oligomer formation of tau protein hyperphosphorylated in cells. J Biol Chem (2014) 0.86
Wild type and P301L mutant Tau promote neuro-inflammation and α-Synuclein accumulation in lentiviral gene delivery models. Mol Cell Neurosci (2011) 0.85
The marine natural-derived inhibitors of glycogen synthase kinase-3beta phenylmethylene hydantoins: In vitro and in vivo activities and pharmacophore modeling. Bioorg Med Chem (2009) 0.82
Prostate-derived sterile 20-like kinases (PSKs/TAOKs) phosphorylate tau protein and are activated in tangle-bearing neurons in Alzheimer disease. J Biol Chem (2013) 0.82
Environmental stress affects the activity of metabolic and growth factor signaling networks and induces autophagy markers in MCF7 breast cancer cells. Mol Cell Proteomics (2014) 0.82
Crosstalk of cell polarity signaling pathways. Protoplasma (2017) 0.81
Bioactive marine drugs and marine biomaterials for brain diseases. Mar Drugs (2014) 0.81
Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies? Oxid Med Cell Longev (2015) 0.80
Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal. World J Diabetes (2015) 0.80
Mechanisms of brain aging regulation by insulin: implications for neurodegeneration in late-onset Alzheimer's disease. ISRN Neurol (2011) 0.78
Dysfunction of microtubule-associated proteins of MAP2/tau family in Prion disease. Prion (2012) 0.78
Morphine Reduces Myocardial Infarct Size via Heat Shock Protein 90 in Rodents. Biomed Res Int (2015) 0.78
BBB-Permeable, Neuroprotective, and Neurotrophic Polysaccharide, Midi-GAGR. PLoS One (2016) 0.77
New application of beta-galactosidase complementation to monitor tau self-association. J Neurochem (2008) 0.77
The tau code. Front Aging Neurosci (2009) 0.76
Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model. Brain (2017) 0.75
Akt and mitogen-activated protein kinase enhance C-type lectin-like receptor 2-mediated platelet activation by inhibition of glycogen synthase kinase 3α/β. J Thromb Haemost (2015) 0.75
Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer's Disease. eNeuro (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci (2004) 7.92
Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet (2004) 2.31
Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proc Natl Acad Sci U S A (2002) 1.96
Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta (2005) 1.95
Transglutaminase and polyamination of tubulin: posttranslational modification for stabilizing axonal microtubules. Neuron (2013) 1.78
Transglutaminase 2 and its role in pulmonary fibrosis. Am J Respir Crit Care Med (2011) 1.68
Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem (2005) 1.67
The low density lipoprotein receptor-related protein 6 interacts with glycogen synthase kinase 3 and attenuates activity. J Biol Chem (2005) 1.54
Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neurochem (2004) 1.49
Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neurochem (2008) 1.38
Site-specific phosphorylation and caspase cleavage differentially impact tau-microtubule interactions and tau aggregation. J Biol Chem (2006) 1.33
Transglutaminase regulation of cell function. Physiol Rev (2014) 1.28
Role of the intracellular domains of LRP5 and LRP6 in activating the Wnt canonical pathway. J Cell Biochem (2005) 1.28
Transglutaminase 2: a molecular Swiss army knife. Biochim Biophys Acta (2011) 1.25
Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease. J Biol Chem (2009) 1.24
Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem (2002) 1.22
Cdk5 phosphorylates p53 and regulates its activity. J Neurochem (2002) 1.22
Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum Mol Genet (2004) 1.19
The role of tau phosphorylation in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res (2006) 1.18
Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. J Biol Chem (2006) 1.17
A caspase cleaved form of tau is preferentially degraded through the autophagy pathway. J Biol Chem (2010) 1.15
The role of tau kinases in Alzheimer's disease. Curr Opin Drug Discov Devel (2010) 1.15
Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes (2006) 1.15
Cyclin-dependent kinase-5 in neurodegeneration. J Neurochem (2004) 1.14
Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem (2005) 1.10
Tissue transglutaminase differentially modulates apoptosis in a stimuli-dependent manner. J Neurochem (2002) 1.10
Truncated tau and Aβ cooperatively impair mitochondria in primary neurons. Neurobiol Aging (2011) 1.09
Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ. J Biol Chem (2004) 1.09
Intracellular localization and activity state of tissue transglutaminase differentially impacts cell death. J Biol Chem (2003) 1.08
Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease. Brain Res Bull (2009) 1.07
Intracellular localization and conformational state of transglutaminase 2: implications for cell death. PLoS One (2009) 1.07
Split GFP complementation assay: a novel approach to quantitatively measure aggregation of tau in situ: effects of GSK3beta activation and caspase 3 cleavage. J Neurochem (2007) 1.07
Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling. FASEB J (2008) 1.06
The role of tau phosphorylation and cleavage in neuronal cell death. Front Biosci (2007) 1.04
Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease. Front Neurol (2013) 1.03
Regulated proteolytic processing of LRP6 results in release of its intracellular domain. J Neurochem (2007) 0.99
The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase. Neurobiol Aging (2006) 0.99
Transglutaminase 2 in neurodegenerative disorders. Front Biosci (2007) 0.99
Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms. J Neurochem (2005) 0.98
Mutant (R406W) human tau is hyperphosphorylated and does not efficiently bind microtubules in a neuronal cortical cell model. J Biol Chem (2003) 0.98
Cytosolic guanine nucledotide binding deficient form of transglutaminase 2 (R580a) potentiates cell death in oxygen glucose deprivation. PLoS One (2011) 0.94
Complete transglutaminase 2 ablation results in reduced stroke volumes and astrocytes that exhibit increased survival in response to ischemia. Neurobiol Dis (2011) 0.93
Tissue transglutaminase directly regulates adenylyl cyclase resulting in enhanced cAMP-response element-binding protein (CREB) activation. J Biol Chem (2003) 0.92
Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin. PLoS One (2013) 0.92
Developmental regulation of tissue transglutaminase in the mouse forebrain. J Neurochem (2004) 0.92
The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics. J Cell Mol Med (2011) 0.91
AES/GRG5: more than just a dominant-negative TLE/GRG family member. Dev Dyn (2010) 0.90
Vena cava and aortic smooth muscle cells express transglutaminases 1 and 4 in addition to transglutaminase 2. Am J Physiol Heart Circ Physiol (2012) 0.90
Mitochondrial-targeted active Akt protects SH-SY5Y neuroblastoma cells from staurosporine-induced apoptotic cell death. J Cell Biochem (2007) 0.89
Tissue transglutaminase overexpression in the brain potentiates calcium-induced hippocampal damage. J Neurochem (2006) 0.89
Mitochondrial permeability transition pore induces mitochondria injury in Huntington disease. Mol Neurodegener (2013) 0.89
The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. J Bioenerg Biomembr (2010) 0.89
Transglutaminases in neurodegenerative disorders. Prog Exp Tumor Res (2005) 0.88
Effects of cyclin-dependent kinase-5 activity on apoptosis and tau phosphorylation in immortalized mouse brain cortical cells. J Neurosci Res (2004) 0.88
Type 2 transglutaminase differentially modulates striatal cell death in the presence of wild type or mutant huntingtin. J Neurochem (2007) 0.88
Transglutaminase 2 facilitates or ameliorates HIF signaling and ischemic cell death depending on its conformation and localization. Biochim Biophys Acta (2012) 0.88
Immortalized cortical neurons expressing caspase-cleaved tau are sensitized to endoplasmic reticulum stress induced cell death. Brain Res (2008) 0.87
Ubiquitin-proteasome system alterations in a striatal cell model of Huntington's disease. J Neurosci Res (2007) 0.87
Activation of glycogen synthase kinase 3beta promotes the intermolecular association of tau. The use of fluorescence resonance energy transfer microscopy. J Biol Chem (2007) 0.87
Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases. Mol Cell Neurosci (2004) 0.87
Metabolic state determines sensitivity to cellular stress in Huntington disease: normalization by activation of PPARγ. PLoS One (2012) 0.87
Increased glutathione levels in cortical and striatal mitochondria of the R6/2 Huntington's disease mouse model. Neurosci Lett (2005) 0.86
Increased expression of Bim contributes to the potentiation of serum deprivation-induced apoptotic cell death in Huntington's disease knock-in striatal cell line. Neurol Res (2008) 0.84
Differential modulation of TCF/LEF-1 activity by the soluble LRP6-ICD. PLoS One (2010) 0.83
Does tissue transglutaminase play a role in Huntington's disease? Neurochem Int (2002) 0.83
The last tangle of tau. J Alzheimers Dis (2008) 0.82
Axin negatively affects tau phosphorylation by glycogen synthase kinase 3beta. J Neurochem (2002) 0.81
Split GFP complementation assay for quantitative measurement of tau aggregation in situ. Methods Mol Biol (2011) 0.81
FRAT-2 preferentially increases glycogen synthase kinase 3 beta-mediated phosphorylation of primed sites, which results in enhanced tau phosphorylation. J Biol Chem (2004) 0.81
Decreases in valosin-containing protein result in increased levels of tau phosphorylated at Ser262/356. FEBS Lett (2011) 0.80
Phosphorylation of PPP(S/T)P motif of the free LRP6 intracellular domain is not required to activate the Wnt/beta-catenin pathway and attenuate GSK3beta activity. J Cell Biochem (2009) 0.79
Tissue transglutaminase is not involved in the aggregate formation of stably expressed alpha-synuclein in SH-SY5Y human neuroblastoma cells. Arch Pharm Res (2004) 0.79
The application of permanent middle cerebral artery ligation in the mouse. J Vis Exp (2011) 0.78
Epigallocatechin-3-gallate enhances clearance of phosphorylated tau in primary neurons. Nutr Neurosci (2015) 0.78
Transient osmotic stress facilitates mutant huntingtin aggregation. Neuroreport (2002) 0.78
Autophagy in Alzheimer's disease. Rev Neurosci (2015) 0.78
New application of beta-galactosidase complementation to monitor tau self-association. J Neurochem (2008) 0.77
Identification of the N-terminal functional domains of Cdk5 by molecular truncation and computer modeling. Proteins (2002) 0.77
Mutant huntingtin aggregates do not sensitize cells to apoptotic stressors. FEBS Lett (2002) 0.77
14-3-3Zeta does not increase GSK3beta-mediated tau phosphorylation in cell culture models. Neurosci Lett (2005) 0.76
Verification of somatic CAG repeat expansion by pre-PCR fractionation. J Neurosci Methods (2004) 0.76
Subcellular localization patterns of transglutaminase 2 in astrocytes and neurons are differentially altered by hypoxia. Neuroreport (2017) 0.75